Cassava's target is the good old Amyloid plaque, the only difference between the other amyloid palque targeting drugs and Sumifilam is that instead removal of the plaque the sumifilam blocks production of amyloid plaque in its misshaped state and therefore the whole cascade of other biomarkers are controled, especially those direcetly involved in inflammation and … Continue reading Cassava Sciences, Hit or Miss? $SAVA $AVXL
I would llike to thank the people who donated to defray my costs. Great thanks to miltonTB for the largest contribution. From the most recent, miltonTB jaimeN garySCH rkd1961 (2x) RichR FinJ I abreviated their emails as I did not ask them for permition to publish their full names. Thank you very much. Would anybody … Continue reading Thank you, for your donations.
Hat tip to Tom Dean. Let's start with a pretty picture. I broke down the "variety" of patients into two groups 6 Patient SUPER RESPONDERS and 9 Patient HC Cohort. What can I say about HC Cohort: In light of other developments it seems that HC Cohort contains some SIGMAR1 Mutated Variants patients who basically … Continue reading Preview of Possible Effect Size in Alzheimer’s Phase 2b/3. $AVXL Blarcamesine ANAVEX2-73.
SLIDE 15. Slide 15 It is long standing tradition that $AVXL formats the data in such way that only a scientist can quickly recognoze the revelance of the data to currrent paradigm of the disease in question. The individual investor is left holding in his hand something so bewildering that I don't dismiss the calls … Continue reading GOING ONE SLIDE AT A TIME.. CTAD 2020. $AVXL BLARCAMESINE
In my list of deliverables for CTAD 2020 I listed in point 5 the achievent of the status of the drug of choice when patients are faced with the diagnosis of Parkinson's. On page 8 of the presentation there is a hint that this is the ultimate goal of $AVXL and the possibility of that … Continue reading Indication Parkinson’s! $AVXL Blarcamesine
List of delivered goods. For the list of goods to be delivered see http://Goods to be delivered Goods delivered. The dosed cohorts beat the placebo with hands down. Analysis coming.Placebo "slower" than the dosed. Goods delivered. Dr Missling talking of other demantias to be soon tackled by Blarcamesine. Point Delivered.Not yet delivered. One out of … Continue reading CTAD 2020 Delivered Goods List. $AVXL
Let us go from the most likely to the least likely. Cognitive Drug Research - Computerized Assesment System - Continuing Attension confirms the AD Phase 2a Phase 2b/3 results with decreased timing in psychomotor skils (relevant to both PD and AD, but mostly for PDD) and cognitive skill as tested by CDR-CA. Background of previous … Continue reading What to Expect from CTAD 2020 Boston. $AVXL Blarcamesine
Before I lose my train of thought...the title should have been; "at 3,285 patients even the dead can walk...". Another of my gross exaggerations. The intrepid Aducanumab adds another $X billion to $BIIB market cap. New analysis claims that there is a glimmer of hope for the drug. I am not a statistician or did … Continue reading Suddenly, Aducanumab (again)! And Biogen Adds Billions in Market Cap. $BIIB $AVXL